Second Korean guidelines for the management of ulcerative colitis.
- Author:
Chang Hwan CHOI
1
;
Won MOON
;
You Sun KIM
;
Eun Soo KIM
;
Bo In LEE
;
Yunho JUNG
;
Yong Sik YOON
;
Heeyoung LEE
;
Dong Il PARK
;
Dong Soo HAN
Author Information
- Publication Type:Review
- Keywords: Colitis, ulcerative; Inflammatory bowel disease; Disease management; Guidelines
- MeSH: Biological Products; Classification; Colitis; Colitis, Ulcerative*; Disease Management; Humans; Incidence; Inflammatory Bowel Diseases; Intestinal Diseases; Korea; Prevalence; Quality of Life; Ulcer*
- From:Intestinal Research 2017;15(1):7-37
- CountryRepublic of Korea
- Language:English
- Abstract: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during exacerbation of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies, including biologics, are currently used for the management of UC. However, many challenging issues exist, which sometimes lead to differences in practice between clinicians. Therefore, the IBD study group of the Korean Association for the Study of Intestinal Diseases established the first Korean guidelines for the management of UC in 2012. This is an update of the first guidelines. It was generally made by the adaptation of several foreign guidelines as was the first edition, and encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC. The specific recommendations are presented with the quality of evidence and classification of recommendations.
